NITD008

NITD008 is an adenosine nucleoside analog with broad-spectrum antiviral activity against various RNA viruses, including flaviviruses (such as dengue virus, Zika virus, West Nile virus, yellow fever virus, and Powassan virus), hepaciviruses (hepatitis C virus), enteroviruses (enterovirus 71), and caliciviruses. Developed by the Novartis Institute for Tropical Diseases, NITD008 acts as a chain terminator of viral RNA synthesis. Upon entering host cells, it is phosphorylated into its active triphosphate form, which competes with natural ATP for incorporation into the nascent viral RNA chain by the viral RNA-dependent RNA polymerase (RdRp), leading to premature chain termination. Although NITD008 demonstrated potent in vitro and in vivo efficacy in animal models, its clinical development was discontinued due to severe toxicity observed in preclinical toxicology studies in rats and dogs.

Other names

7-(2-C-Ethynyl-b-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine7-(2-C-Ethynyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine7-Deaza-2'-C-acetylene-adenosine7-Deaza-2'-C-acetyleneadenosine7-Deaza-2'-C-ethynyl-adenosine7-Deaza-2'-C-ethynyladenosine